No survival benefit has generally been observed in these studies, attributed to the important crossover to TKI as a second-line treatment in the chemotherapy arms, except for afatinib in patients with a del19 EGFR mutations in the tumor [21]. The gene discussed is EGFR; the disease is neoplasm.